Abstract: Objective To observe the clinical curative effects of compound diisopropylamine dichloroacetate (CDDI) in treating fatty liver disease induced by ta
moxifen(TAM) and to provide theoretical basis for its clinical application.Methods 72 cases of breast cancer patients with fatty liver disease induced by TAM were randomly divided into control group(n=38) and treatment group(n=34).The patients in control group were treated with   basic treatment alone.The patients in treatment group were injected intravenously  with CDDI 80 mg  once daily for 4 weeks in addition to basic treatment.The changes of clinical symptoms,liver function enzymes,blood lipids and liver imaging   of the patients in two groups were observed before and after treatment.The efficacy and safety of drugs were examined.Results After treatment，the total effective rates were 82.3% in treatment group and 23.7% in cont
rol group,there was significantly difference between two groups（P<0.01）.Compared with before treatment,the contents of alanine aminotransferase (ALT),total cholesterol (TC),and triglyceride (TG)of the patients in treatment group were significantly decreased after treatment（P<0.05）;and there also were  significant differences compared with control group after treatment(P<0.05).There were no significant differences of the
 contents of ALT,TC and TG in control group between before treatment and after treatment（P>0.05）.No severe adverse drug reactions were found in two groups during treatment period.Conclusion  CDDI could be used as a effective drug in the treatment of fatty liver disease induced by TAM.


Key words: diisoprorylamine/therapeutic use, dichloroacetate/therapeutic use, tamoxifen, fatty liver diseases